PAPER

Check for updates

β-Peptides incorporating polyhydroxylated cyclohexane β-amino acid: synthesis and conformational study†‡

David Reza, [ID] [a] Rosalino Balo, [ID] [a,c] José M. Otero,[a] Ai M. Fletcher,[c] Rebeca García-Fandino, [ID] [a,b] Víctor M. Sánchez-Pedregal, [ID] [b] Stephen G. Davies, [ID] [c] Ramón J. Estévez [ID] [a,b] and Juan C. Estévez [ID] ⋆[a,b]

We describe the synthesis of trihydroxylated cyclohexane β-amino acids from (−)-shikimic acid, in their *cis* and *trans* configuration, and the incorporation of the *trans* isomer into a *trans*-2-aminocyclohexane-carboxylic acid peptide chain. Subsequently, the hydroxyl groups were partially or totally deprotected. The structural study of the new peptides by FTIR, CD, solution NMR and DFT calculations revealed that they all fold into a 14-helix secondary structure, similarly to the homooligomer of *trans*-2-aminocyclo-hexanecarboxylic acid. This means that the high degree of substitution of the cyclohexane ring of the new residue is compatible with the adoption of a stable helical secondary structure and opens opportunities for the design of more elaborate peptidic foldamers with oriented polar substituents at selected positions of the cycloalkane residues.

Introduction

β-Amino acids are attractive building blocks for the synthesis of peptidomimetics because of their propensity to fold into diverse secondary structures (such as helices, turns, sheets, and hairpins) in short peptide sequences.[1–6] In addition, their resistance to protease degradation[7,8] is beneficial for therapeutic applications.[4,9–14]

Carbocyclic β-amino acids are of special interest due to the limited flexibility derived from their constrained cyclic structures and have been demonstrated to act as particularly strong helix or turn inducers.[5,15–17] This has led, for instance, to the design of bioactive β-peptides,[18–20] self-assembling nanomaterials[21–24] and catalysts.[25,26]

aCentro Singular de Investigación en Química Bolóxica e Materiais Moleculares (CIQUS), Departamento de Química Orgánica. Universidade de Santiago de Compostela, c/Jenaro de la Fuente s/n, 15782 Santiago de Compostela, Spain. E-mail: juancarlos.estevez@usc.es

bDepartamento de Química Orgánica, Universidade de Santiago de Compostela, Avda. das Ciencias s/n, 15782 Santiago de Compostela, Spain

cChemistry Research Laboratory, Department of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK

†This paper is dedicated to Prof. Joan Bosch on the occasion of his 75th birthday.

‡Electronic supplementary information (ESI) available: Copies of ^{1}H and ^{13}C NMR spectra for compounds **3**, **4**, **5**, **6**, **7**, **8** and **11**. FT-IR, CD, NMR structural analysis and DFT calculations for compounds **14**, **15**, **16**. Single-crystal X-ray data of **3**. CCDC 2192947. For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/10.1039/d3ob00906h

The folding properties of carbocyclic β-peptidic foldamers have been widely studied. Pioneering work demonstrated that homooligomers of *trans*-2-aminocyclohexanecarboxylic acid (*trans*-ACHC) fold as a robust 14-helix in short peptide sequences[15,27] while homooligomers of *trans*-2-aminocyclo-pentanecarboxylic acid (*trans*-ACPC) fold as a 12-helix[16,28,29] in the crystal and in solution. Other secondary structures can be accessed by modification of the backbone stereochemical configuration[30,31] or the side chains[32,33] of homooligomers. Another strategy to tune the peptide secondary structure has been the combination of two or more β-amino acids into heterooligomers.[6,34–37] Peptides containing the *cis*-ACHC diastereoisomer have also been studied. Homochiral oligomers of *cis*-ACHC do not form helical structures, although it has been shown to participate in helical folds of heterooligomers and hybrid peptides.[33,38,39]

Most of these studies have been carried out with highly hydrophobic compounds because the number of foldamers containing cyclic β-amino acid monomers functionalized with polar substituents is still limited.[6] The most frequent strategy to obtain polar or water soluble foldamers based on cyclic β-amino acids has been the synthesis of heterooligomers of apolar *trans*-ACPC or *trans*-ACHC residues with structurally simple polar acyclic β-amino acids holding a polar group in their side chain (*e.g.* β-serine or β-lysine).[19,35,40–44] Other examples have the polar group in an otherwise structurally simple cyclic amino acid, as the *trans*-4-aminopyrrolidine-3-carboxylic acid (*trans*-APC),[18,20,34] *trans*-DCHC,[45,46] or an aza-ACPC analogue.[47]

This journal is © The Royal Society of Chemistry 2023

Org. Biomol. Chem., 2023, **21**, 8535–8547 | **8535**

Polyhydroxylated cycloalkane β-amino acids are particularly interesting targets, because their rich functionality makes them useful scaffolds for the access of a variety of lipo- or hydrosoluble peptides, by protection or deprotection of their hydroxy substituents. In addition, they can bear pharmacophoric groups in well defined spatial orientations, a property that may facilitate their interaction with biological receptors, or with substrates if the goal is to use them as peptidic catalysts. Some previous work on the stereoselective synthesis of mono-, di-, tri- and tetrahydroxylated cycloalkane β-amino acids has been reported but, to our knowledge, their incorporation into peptides has not yet been addressed[17,36,48–50] except in one example.[51]

In connection with our interest in polyhydroxylated cycloalkane amino acids and their peptides,[52,53] we present here an efficient stereoselective synthesis of two new polyhydroxylated cyclohexane β-amino acids with *cis*- and *trans*-configurations, starting from commercially available (−)-shikimic acid. The newly synthesized *trans*-β-amino acid was incorporated into a short heterooligomeric peptide also containing *trans*-ACHC and its structure in solution has been studied.[54]

Results and discussion

Synthesis of polyhydroxylated cyclohexane β-amino acids 5 and 8

(−)-Shikimic acid is an attractive starting material on account of its convenient structural properties: a preformed cyclohexane ring bearing an α,β-unsaturated carboxylic acid moiety and three hydroxy substituents with well-defined spatial orientations.[55,56] The synthetic plan involved a stereoselective Michael addition of dibenzylamines to α,β-unsaturated esters, in this case methyl shikimates.[57]

Addition of the known shikimate ester **1**[53] to a cooled (−78 °C) solution of lithium amide (**R**)-**2** in THF provided, after 2 h reaction followed by work-up with saturated aq. ammonium chloride solution, a mixture of *cis*-β-amino acid **3** (major component, 61% yield) and *trans*-β-amino acid **6**

(minor component, 5% yield). In addition, reaction of compound **3** with a 2 M solution of NaOMe in MeOH resulted in its isomerization to compound **6** (89% yield). Compounds **3** and **6** were easily identified from their analytical and spectroscopic data. The structure of compound **3** was unambiguously established by X-ray crystallography (Scheme 1).

Catalytic hydrogenation of compound **3**, using Pd(OH)₂, provided amino acid ester **4**, which upon reaction with 6 M HCl resulted in the formation of the new trihydroxylated *cis*-2-aminocyclohexanecarboxylic acid **5** (76% yield over the two steps). Similarly, compound **6** provided the new trihydroxylated *trans*-2-aminocyclohexanecarboxylic acid **8** (77% yield over the three steps), *via* compound **7**.

The favoured Michael addition of the chiral amide (**R**)-**2** to the *si-face* of the α,β-unsaturated carboxylic acid ester moiety of **1** can be justified as a case of double chiral induction by the reagent and the substrate, leading to the stereospecific formation of the intermediate enolate shown in Scheme 2 by the complexation of the litium ion with the carbonyl oxygen and the amino atoms. Then, protonation of this enolate can occur according either to *path a* (more favoured) or *path b* (less favoured), the result being the formation of a mixture of compound **3** (kinetic isomer, major component) and compound **6** (thermodynamic isomer, minor component) (Scheme 2).[58,59]

We chose to introduce the nitrogen substituent with amide (**R**)-**2** because it highly favours the formation of the *cis*-β-amino ester **3** (kinetic product), which can then be quantitatively transformed into the *trans*-β-amino ester **6** (thermodynamic product). Although dibenzylamine could also be tried, our previous experience with similar compounds indicated that it would likely lead to a mixture of both isomers in uncertain proportions.[53]

Synthesis of pentamers 14, 15 and 16, containing *trans*-polyhydroxylated cyclohexane β-amino acid 8

The newly synthesized beta amino acids **5** and **8** can be used as components of peptidomimetics. Oligomers of *trans*-ACHC


Scheme 1

8536 | *Org. Biomol. Chem.*, 2023, **21**, 8535–8547

This journal is © The Royal Society of Chemistry 2023

induction by the reagent
induction by the substrate

G = OTBS; R = CH₂Ph; R' = CH(CH₃)Ph

Scheme 2

are known to adopt the 14-helix secondary structure.[15,16,27] while the conformational properties of peptides containing *cis*-ACHC and derivatives are more uncertain[33,38,39] and depend on the specific composition in heterooligomers and/or hybrid peptides. With the aim of obtaining a predictable structure, in this work we focused on the *trans*-β-amino acid **8**. Therefore, we synthesized pentamer **14** that has the functionalized β-amino acid **8** in the central position, flanked by *trans*-ACHC residues (Scheme 3). Sequential deprotection of the hydroxyls of **14** led to pentamers **15** and **16**, which allowed us to study the influence of their degree of polarity and steric hindrance on their propensity to adopt the 14-helix secondary structure.

The synthesis of the target pentamers **14–16** was performed in solution starting from compound **7**, an orthogonally pro-

tected equivalent of β-amino acid **8**, that was coupled with dimer **10** (Boc-*trans*-(ACHC)₂), obtained from dimer **9** (Boc-*trans*-(ACHC)₂-OBn),[27] to give trimer **11** in 93% yield characterized from their spectroscopic and spectrometric properties (see ESI‡). Dimer **13** (*trans*-(ACHC)₂-OBn) was also obtained from (Boc-*trans*-(ACHC)₂-OBn) (see the ESI‡). Treatment of trimer **11** with LiOH to give the acid derivative **12** (92%), followed by coupling with dimer **13**, gave the expected pentamer **14** (Scheme 3).

Pentamer **14** was transformed into the monohydroxylated pentamer **15** in 76% yield by treatment with TBAF. Finally, pentamer **15** was transformed into the trihydroxylated pentamer **16** when submitted to a hydrolysis reaction catalyzed by acetic acid. All three pentamers **14–16** were purified and then subjected to structural studies in solution.

Scheme 3

This journal is © The Royal Society of Chemistry 2023

Org. Biomol. Chem., 2023, **21**, 8535–8547 | **8537**

Infrared spectroscopy

We measured the ATR-FTIR spectra of dimer **9**, trimer **11** and the three pentamers **14**–**16** in the solid state to assess the formation of hydrogen bonds. Significant differences were observed for the vibration of the Amide A band, with clearly lower wavenumber values for pentamers **14** (3281 cm^{-1}) and **16** (3269 cm^{-1}) than for dimer **9** (3297 cm^{-1}) and trimer **11** (3327 cm^{-1}) as shown in Fig. 1A. The vibration Amide II band shifts to higher wavenumbers from dimer **9** (1533 cm^{-1}) and trimer **11** (1528 cm^{-1}) to pentamers **14** (1536 cm^{-1}), **15** (1547 cm^{-1}) and **16** (1547 cm^{-1}) (Fig. 1B). Differences in the Amide I band of the five compounds were negligible.

The signals of Amide A and Amide II are compatible with the increase of hydrogen bonding as the polyamide chain gets longer. Such behaviour is the expected for a higher level of secondary structure formation as oligomer length increases. Upon formation of H-bonds, vibration frequencies of Amide A shift to lower wavenumbers, while vibrations of Amide II shift to higher wavenumbers. However, this information is not sufficient to determine what fold (*e.g.* what helix type) is adopted by the peptide.[60,61]

CD spectroscopy

Circular dichroism (CD) spectroscopy can be used to establish the secondary structure of polyamide chains, since each type of secondary structure gives rise to a characteristic CD spectrum in the far ultraviolet region (190–240 nm).[62] In fact, it has been used routinely to establish the secondary structure of peptide α-amino acids and even establish the proportion of

each of these secondary structures in natural proteins.[63] For the case of polyamides constituted by other than α-amino acids, there is no simple way to correlate far-ultraviolet CD spectra with their specific conformations,[64] but comparison of CD data from new and existing polyamides can provide useful information if structures are similar.

The CD spectra of dimer **9**, trimer **11** and pentamer **14**, at 1 mM concentration in methanol (Fig. 2A), present an ellipticity maximum in the far ultraviolet region around 220 nm, that arises from the backbone amide groups. The intensity of this maximum increases with β-peptide length.

We then compared the CD spectra of the three differently protected pentamers **14**–**16**, at 1 mM concentration in methanol solution (Fig. 2A). The three pentamers present an absorption maximum in the far ultraviolet region of about 220 nm. The slight shift of θ_{max} (221 nm for **14**, 221 nm for **15** and 217 nm for **16**) can be justified assuming that the conformation of the helices are slightly different when the substituted cyclohexane ring is strained by the acetonide group (**14** and **15**) to when this acetonide is not present (**16**). Indeed, the value of θ_{max} of **16** is identical to the reported value for the unsubstituted *trans*-ACHC oligomers (217 nm). Slight shifts of the CD maxima have also been attributed to different populations of the 14-helix averaging with other conformers existing in solution.[27,43]

Additionally, we performed CD experiments with pentamer **14** by changing the concentration and temperature (Fig. 2B). Increasing the concentration resulted in higher intensity but no shift of the θ_{max}, consistent with the molecule not aggregating in this concentration range. More interestingly, negligible changes occurred upon increasing temperature from 0 °C to 25 °C, demonstrating the overall stability of the structure.

NMR spectroscopy

We analyzed the structure of pentamers **14**–**16** by NMR spectroscopy in CDCl$_3$, DMSO-d_6, and methanol-d_3 solutions. ^{1}H NMR spectra of peptides **14** and **15** in CDCl$_3$ solution had multiple amide HN peaks and broad lines, indicating more than a single conformation and aggregation. Peptide **16** formed a gel in CDCl$_3$ and no further NMR studies were done in this solvent.


Fig. 1 $\bar{\nu}_{max}$ of the ATR-FTIR spectra of peptides **9**, **11**, **14**, **15** and **16** in the Amide A (A) and Amide II (B) regions.


Fig. 2 (A) CD spectra of peptides **9**, **11**, **14**, **15** and **16** in methanol (*c* = 1 mM). (B) Concentration and temperature dependence of the CD spectra of peptide **14** in methanol.

8538 | *Org. Biomol. Chem.*, 2023, **21**, 8535–8547

This journal is © The Royal Society of Chemistry 2023

Fig. 3 Summary of detected ROESY cross-peaks of peptides **14–16** in DMSO-d_6 solution. Arrows representing the strong intraresidual HN(i)/Hα(i) cross-peaks have been omitted for clarity. Intensities: HN(i)/Hα(i − 1) and Hα(i)/Hb(i + 3), strong; HN(i)/Hβ(i), medium; HN(i)/Hβ(i + 2), medium or unknown due to peak overlap. The complete tables of ROESY cross-peak intensities are included in the ESI.‡

Dispersion of chemical shifts in DMSO-d_6 solution was sufficient to analyze the NMR spectra of compounds **14–16**.[65] Amide HN resonances were well dispersed in the 1D proton spectra, suggesting a high population of a single well-defined conformation of each compound. Residue-specific assignments of the backbone HN, Hα, and Hβ protons were made based on a combination of COSY, TOCSY and ROESY spectra. The other side-chain resonances were typically not assigned due to extensive overlap (see tables of assignments in ESI‡).

The backbone fold of the peptides was determined from NOE contacts characteristic of the 14-helix secondary structure (Fig. 3), like the strong long-range Hα(i)/Hβ(i + 3) and sequential HN(i)/Hα(i − 1) NOEs, that correspond to H–H distances of ≈2.2–2.6 Å in a 14-helix.[15,37,42,65] Further support to the 14-helix fold comes from the HN(i)/Hβ(i + 2) and the HN(i)/Hβ(i + 3) NOE peaks of medium intensity, that correspond to distances in the range of 3.0–3.5 Å (see the ESI for tables of NOEs of the three peptides‡). Some NOEs from residue 3 to the terminal t-Bu and OBn groups are also compatible with the 14-helix conformation. The uniform amide three-bond coupling values $^3J_{(HNi–Hβi)}$ in the range of 7–9 Hz (Table 1) correspond to dihedral angles of the HN(i)–CHβ(i) fragments close to 160°,[66,67] that is also characteristic of the 14-helix secondary structure.[15,65]

Restrained molecular dynamics calculated with XPLOR-NIH[68,69] using the NOE and scalar coupling data led to structures with the 14-helical fold for peptides **14–16**. These models were further optimized using density functional theory

(DFT) calculations that employed the hybrid density functional M052X[70] with the 6-31G(d) basis set. DFT calculations were performed using Gaussian 09.[71]

To analyze the alignment of the atoms intervening in hydrogen bonding, we considered the distances and angles listed in Table 2. In principle, as it is stated in the IUPAC definition for hydrogen bonds, the closer the X–H⋯Y angles angle is to 180°, the stronger is the hydrogen bond and the shorter is the H⋯Y distance.[72] The structure of **16** resembled very closely the geometry of the crystallographic structure of the *trans*-ACHC homohexamer (RMSD = 0.236 Å for backbone atoms Cα, Cβ, N and C(=O) of residues 1–5; Fig. 4),[15] presenting the shortest O⋯N and O⋯H distances and the largest C=O⋯H angles. In contrast, the geometry of the hydrogen bonds of peptides **14** and **15** in the DFT optimized models was a bit distorted, while keeping the 14-helix fold, due to the steric constraints imposed by the substituents on positions γ, δ and ε of residue 3 (Fig. 5). This agrees well with the CD data recorded in methanol, as the maximum ellipticity of peptides **14** and **15** deviates a few nm from the values of the *trans*-ACHC homohexamer and peptide **16**. Further support to the 14-helix fold derives from the NMR amide proton temperature coefficients (Table 1). The usual interpretation is that intramolecularly hydrogen-bonded HN groups give small values, while solvent-exposed HN groups give larger values.[65] In peptides **14–16**, the HN of residues 1–3 participate in intramolecular hydrogen

Table 1 Properties of amide HN protons (DMSO-d_6, 500 MHz). Scalar couplings were determined at 298 K. Temperature coefficients in −ppb K^{-1} units

	$^3J_{HN-Hβ}$ (Hz)			T-coef (−ppb K^{-1})		
	14	**15**	**16**	**14**	**15**	**16**
HN1	8.3	8.5	8.8	7.3	7.5	5.2
HN2	7.9	8.3	8.6	5.6	4.9	4.3
HN3	8.3	9.2	7.3	0.9	1.7	3.4
HN4	8.4	8.6	8.6	9.0	9.2	8.2
HN5	7.9	8.6	8.9	5.2	5.4	4.9

Table 2 Geometrical parameters (distances in Å and angles in degrees) for peptides **14–16**, optimized using DFT calculations at M052X/6-31G (d) level

	O⋯N	O⋯H	O⋯H–N	C=O⋯H
14	2.91	1.94	160.2	138.6
	3.06	2.20	142.9	144.4
	3.04	2.18	142.3	143.0
15	2.91	1.93	161.8	138.4
	3.22	2.36	141.6	140.2
	3.00	2.18	138.1	148.0
16	2.92	1.96	156.6	154.3
	2.95	2.01	153.5	174.9
	2.96	2.03	153.1	162.8

solvent exposed HN(4) gives the largest value (≈-9 ppb K^{-1}) in the three peptides.

We also studied peptide **16** in CD$_3$-OH solution at 500 and 750 MHz at temperatures 273 and 298 K. The amide HN peaks in the 1D ^{1}H spectrum were consistent with the existence of a major conformer and small amounts of other species. There is some extent of chemical exchange in the amide region of the NOESY and some peaks of the minor species exchange with the solvent HO proton at $\delta_H \approx 5.1$ ppm. Although chemical shift dispersion of the Hα(i) peaks was poor, assignment of backbone resonances of the major conformer was possible with spectra recorded at 750 MHz. Amide HN three-bond scalar couplings, temperature coefficients and NOESY peak pattern were similar to those observed for the same peptide in DMSO-d_6 solution and hence compatible with the 14-helix conformation. Amide three-bond couplings $^3J_{(HNi-H\beta i)}$ were in the range of 8.2–9.2 Hz, that correspond to dihedral angles $\varphi_i \approx 160°$ according to the Karplus relationship.[66,67] The small amide temperature coefficients of residues 1–3 (values −5.2, −4.0 and −4.2 ppb K^{-1}, respectively) are consistent with the participation in intramolecular hydrogen bonds. Most of the characteristic NOEs of the 14-helix[15,65] were detected in the NOESY spectrum (t_{mix} = 500 ms, T = 273 K, 750 MHz), like the strong intraresidue HN(i)/Hα(i) and sequential HN(i)/Hα(i − 1) peaks. All of the expected intra-residue HN(i)/Hβ(i) and inter-residue HN(i)/Hβ(i + 2) [i = 1, 2, 3] peaks also appear in the NOESY with reasonable intensities for the H–H distances

Fig. 4 Alignment of peptide **16** and the crystallographic structure of the ACHC homohexamer reported by Gellman *et al.*[15] Backbone Cα, Cβ, N and C(=O) atoms of residues 1–5 were selected for the alignment of the two molecules (rmsd = 0.236 Å). Colours: C of peptide **16** green, C of ACHC homohexamer grey, O red, N blue, amide H^N and hydroxyl H^O white. Hydrogen atoms bound to carbons have been omitted for clarity.

bonds and, accordingly, the HN of residues 2 and 3 give the smallest coefficients. The larger value of the HN(1) temperature coefficient is consistent with fraying at the terminus. The


Fig. 5 Geometry of peptides **14–16** optimized using DFT calculations at M052X/6-31G(d) level. Colours: C green, O red, N blue, Si black, amide H^N and hydroxyl H^O white. Hydrogen atoms bound to carbons have been omitted for clarity. Hydrogen bonds are shown as dotted purple lines.

(≈3.0 and ≈3.4 Å, respectively) in the canonical 14-helix conformation. Finally, two important strong long-range contacts are expected for Hα(i)/Hβ($i + 3$) [$i = 1$ or 2, distance <2.5 Å]; those peaks do appear in the NOESY spectrum, although assignment is only tentative due to overlap of several Hα protons with very close chemical shifts. All these observations are in agreement with the major species being in the 14-helix conformation in methanol.

In summary, the FTIR, CD, NMR and DFT calculations data support that pentamers **14–16** adopt the expected 14-helical fold, similarly to homooligomers of *trans*-ACHC, regardless the functionalization of residue 3. The strain of the cyclohexane ring due to the fused five membered acetonide ring (in pentamers **14–15**) or the bulky hydrophobic TBS group protecting the Oε(3) atom (in pentamer **14**) does not impede the adoption of a backbone conformation compatible with the 14-helix (*i.e.* that placing the carbonyl and the amino groups in equatorial orientation), at least in these short peptides. Although CD spectra cannot be measured in DMSO, but only in methanol, the solution NMR analysis of peptide **16** in DMSO-d_6 and methanol-d_3 revealed that it adopts essentially the same fold in both solvents.

Conclusions

In conclusion, we present here a stereocontrolled synthesis of highly functionalized cyclohexane β-amino acids from (−)-shikimic acid that has allowed the synthesis, on the gram scale, of the first trihydroxylated cyclohexane β-amino acids described having *cis*- or *trans*- relative configurations in their free form (**5** and **8**) or orthogonally protected for their incorporation into peptides (**4** and **7**, respectively). The availability of highly functionalized β-amino acids is useful for obtaining cycloalkane β-peptides with polar side chains, including the previously unreported polyhydroxylated cycloalkane β-amino acids, of potential interest in chemical biology and material sciences. As an example, herein we present the synthesis of a pentameric β-peptide containing the orthogonally protected *trans* β-amino acid **7** at an internal position, flanked by apolar *trans*-ACHC residues. We also demonstrate the chemical stability of this class of peptides (by sequentially deprotecting the hydroxyl groups of pentamer **14** to give pentamers **15** and **16**), and their conformational stability, as the structural studies revealed that they adopt a 14-helix fold despite the bulky substituents of the cyclohexane ring. Work to construct more elaborate peptides containing combinations of this new polar residue with apolar ones is in progress to obtain functionalized and potentially amphiphilic peptides.

Experimental section

General information

All non-aqueous reactions were carried out under a positive atmosphere of argon in flame-dried glassware unless otherwise

stated. Air- and moisture-sensitive liquid reagents were added by dry syringe or cannula. Anhydrous tetrahydrofuran (THF) was freshly distilled from sodium/benzophenone under argon and all other solvents and reagents were used as obtained from commercial sources without further purification unless stated. Flash chromatography was performed using 60 Merck 230–400 mesh (flash, 0.04–0.063) silica. Thin layer chromatography (tlc) was carried out on aluminium backed sheets coated with 60 GF254 silica. Plates were developed using a spray of 0.2% w/v cerium(IV) sulfate and 5% ammonium molybdate in 2 M sulfuric acid, or in 5% w/v ninhydrin in methanol. ^{1}H- and ^{13}C-NMR spectra were recorded on Varian Mercury 300 (300 MHz for ^{1}H and 75 MHz for ^{13}C) spectrometers at room temperature unless otherwise stated. All chemical shifts are quoted on the δ scale using residual solvent as internal standard; s, d, t, q, m, and br designate singlet, doublet, triplet, quadruplet, multiplet, and broad, respectively. Coupling constants (J) are measured in Hz. Mass spectra were recorded on a Micromass VG-Autospec spectrometer [by chemical ionisation (NH₃, CI) or electrospray techniques, as stated]. Infrared spectra were recorded on a FT-IR Mattson Cygnus-100 spectrometer. Only the characteristic peaks are quoted (in units of cm^{-1}); st, m, and br designate strong, medium, and broad, respectively. All spectra were measured in KBr unless otherwise stated. Optical rotations were measured on a Jasco DIP-370 polarimeter with a path length of 0.5 dm and Na (589 nm) lamp. Concentrations are given in g per 100 mL.

Methyl (3aR,4S,5S,7R,7aR)-4-(benzyl((R)-1-phenylethyl)amino)-7-(($tert$-butyldimethylsilyl)oxy)-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-5-carboxylate (3) and methyl (3aR,4S,5R,7R,7aR)-4-(benzyl((R)-1-phenylethyl)amino)-7-(($tert$-butyldimethylsilyl)oxy)-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-5-carboxylate (6)

n-Butyllithium (1.6 M hexanes solution, 4.6 mL, 2.0 eq.) was added to a solution of (R)-N-benzyl(1-phenylethyl) amine (1.57 mL, 7.36 mmol, 2.0 eq.) in dry THF (46 mL) at −78 °C and stirred for 30 min at the same temperature. To this mixture was added a solution of **1** (1.26 g, 3.68 mmol) in dry THF (12.5 mL) at −78 °C. After stirring the mixture for 2 h at the same temperature, a saturated solution of NH₄Cl was added and the mixture was allowed to warm to room temperature over 30 min and extracted with Et₂O (3 × 75 mL). The organic layers combined were washed with a 10% solution of citric acid (75 mL), a saturated solution of NaHCO₃ (75 mL), and brine (75 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash column chromatography (Et₂O/hexanes 1 : 20) to give **3** (1.24 g, 61%) and **6** (0.10 g, 5%), both as a colorless oils.

Compound 3. $[\alpha]_D^{23}$: −29.1 (c 2.8, CHCl₃). **^{1}H-NMR-(CDCl₃, 300 MHz, ppm):** 0.02 (s, 3H, CH₃), 0.06 (s, 3H, CH₃), 0.85 (s, 9H, C(CH₃)₃), 1.33 (d, J = 7.1 Hz, 3H, N–CH–CH_3), 1.36 (s, 3H, CH₃), 1.52 (s, 3H, CH₃), 1.70–1.85 (m, 2H, CH₂), 2.52 (td, J = 8.3, 6.1 Hz, 1H, CH–CO₂Me), 3.40–3.50 (m, 4H, CH₃–O, CH–

This journal is © The Royal Society of Chemistry 2023

Org. Biomol. Chem., 2023, **21**, 8535–8547 | **8541**

N), 3.65 (q, J = 7.1 Hz, 1H, N–CH–CH$_3$), 3.87 (d, J = 13.8 Hz, 1H, CHH–N), 3.95–4.05 (m, 2H, 2× CH–O), 4.09 (d, J = 13.8 Hz, 1H, CHH–N), 4.58 (t, J = 5.9 Hz, 1H, CH–O), 7.17–7.50 (m, 10H, 10× Ar–H). **^{13}C-NMR (CDCl$_3$, 75 MHz, ppm):** −4.8 (CH$_3$), −4.4 (CH$_3$), 18.2 (C), 25.7 (2× CH$_3$), 25.9 (3× CH$_3$), 28.1 (CH$_3$), 31.9 (CH$_2$), 43.6 (CH), 51.5 (CH$_3$), 52.9 (CH$_2$), 56.1 (CH), 57.8 (CH), 71.3 (CH), 75.1 (CH), 80.9 (CH), 107.4 (C), 126.8 (CH-Ar), 126.9 (CH-Ar), 128.0 (2× CH–Ar), 128.3 (2× CH-Ar), 128.4 (2× CH-Ar), 128.8 (2× CH-Ar), 141.2 (C), 143.2 (C), 174.3 (C=O). **HRMS (ESI$^+$):** calculated for C$_{32}$H$_{48}$NO$_5$Si [M + H]$^+$, 554.3296; found, 554.3296. **IR (cm^{-1}):** 1738 (C=O).

Compound 6. $[\alpha]_D^{23}$: +29.6 (c 7.1, CHCl$_3$). **^{1}H-NMR (CDCl$_3$, 300 MHz, ppm):** 0.06 (s, 3H, CH$_3$), 0.08 (s, 3H, CH$_3$), 0.87 (s, 9H, 3× CH$_3$), 1.32 (s, 3H, CH$_3$), 1.38 (s, 3H, CH$_3$), 1.44 (d, J = 6.8 Hz, 3H, CH$_3$), 1.67 (dtd, J = 13.8, 3.9, 1.1 Hz, 1H, CHH), 1.92 (ddd, J = 13.8, 11.6, 2.3 Hz, 1H, CHH), 3.00 (td, J = 11.5, 3.7 Hz, 1H, CH–CO), 3.35 (dd, J = 11.4, 7.1 Hz, 1H, CH–N), 3.57 (s, 3H, CH$_3$–O), 3.94 (s, 2H, CH$_2$–N), 4.02–4.14 (m, 3H, 2× CH–O + N–CH–CH$_3$), 4.44 (dd, J = 7.1, 5.8 Hz, 1H, CH–O), 7.12–7.39 (m, 10H, 10× Ar-H). **^{13}C-NMR (CDCl$_3$, 75 MHz, ppm):** −4.9 (CH$_3$), −4.8 (CH$_3$), 18.1 (C), 18.7 (C), 25.8 (3× CH$_3$), 26.3 (CH$_3$), 27.9 (CH$_3$), 31.6 (CH$_2$), 40.1 (CH), 51.1(CH$_2$), 51.7 (CH$_3$), 58.4 (CH), 60.7 (CH), 67.4 (CH), 75.6 (CH), 78.4 (CH), 108.6 (C), 126.4 (CH-Ar), 126.5 (CH-Ar), 127.8 (2× CH-Ar), 128.0 (2× CH-Ar), 128.3 (2× CH-Ar), 128.5 (2× CH-Ar), 141.8 (C), 145.1 (C), 175.5 (C=O). **HRMS (ESI$^+$):** calculated for C$_{32}$H$_{48}$NO$_5$Si [M + H]$^+$, 554.3296; found, 554.3295. **IR (cm^{-1}):** 1738 (C=O).

Methyl (3a*R*,4*S*,5*R*,7*R*,7a*R*)-4-(benzyl((*R*)-1-phenylethyl)amino)-7-((*tert*-butyldimethylsilyl)oxy)-2,2-dimethylhexahydrobenzo[*d*][1,3]dioxole-5-carboxylate (6)

Compound 3 (0.960 g, 1.73 mmol) was stirred in a solution of 2 M NaOMe in MeOH, freshly prepared (2.55 g of Na in 54 mL of dry MeOH at 0 °C), for 40 h at room temperature. The solvent was evaporated at reduced pressure and the residue was redissolved in DCM (50 mL) and washed with brine (2 × 50 mL). The combined organic layers were dried over Na$_2$SO$_4$, filtered and concentrated. The residue was purified by flash chromatography (AcOEt/Hex 1 : 20) to give 6 (0.85 g, 1.54 mmol, 89%) as a colorless oil.

Methyl (3a*R*,4*S*,5*S*,7*R*,7a*R*)-4-amino-7-((*tert*-butyldimethylsilyl)oxy)-2,2-dimethylhexahydrobenzo[*d*][1,3]dioxole-5-carboxylate (4)

Pd(OH)$_2$/C at 20% (0.075 g (50 wt%)) was added over a deoxygenated solution of 3 (0.150 g, 0.27 mmol) in AcOEt (6 mL). This mixture was stirred under hydrogen over 15 h at rt. Then, the solution was filtered through Celite and washed with AcOEt. The solvent was dried under vacuum and the residue was purified by flash chromatography (AcOEt/Hex 3 : 1) to give 4 (0.086 g, 0.24 mmol, 88%) as a colorless oil. $[\alpha]_D^{23}$: −34.9 (c 0.4, CHCl$_3$). **^{1}H-NMR (CDCl$_3$, 300 MHz, ppm):** 0.06 (m, 6H, 2× CH$_3$), 0.87 (s, 9H, C(CH$_3$)$_3$), 1.33 (s, 3H, CH$_3$), 1.45 (s, 3H, CH$_3$), 1.86–2.02 (m, 2H, CH$_2$), 2.84 (ddd, J = 9.2, 6.0, 4.0 Hz,

1H, CH–CO), 3.36 (t, J = 4.2 Hz, 1H, CH–N), 3.68 (s, 3H, CH$_3$–O), 3.86 (dt, J = 7.6, 5.5 Hz, 1H, CH-OTBS), 3.99 (t, J = 5.5 Hz, 1H, CH–O), 4.19 (dd, J = 5.6, 4.3 Hz, 1H, CH–O). **^{13}C-NMR (CDCl$_3$, 75 MHz, ppm):** −4.9 (CH$_3$), −4.7 (CH$_3$), 18.1 (C), 25.8 (3× CH$_3$), 26.0 (CH$_3$), 28.1 (CH$_3$), 29.2 (CH$_2$), 41.4 (CH), 50.2 (CH), 51.7 (CH$_3$), 70.9 (CH), 79.1 (CH), 79.3 (CH), 108.4 (C), 174.0 (C=O). **HRMS (ESI$^+$):** calculated for C$_{17}$H$_{34}$NO$_5$Si [M + H]$^+$, 360.2201; found, 360.2200. **IR (ν, cm^{-1}):** 3388 (NH), 1735 (C=O).

Methyl (3a*R*,4*S*,5*R*,7*R*,7a*R*)-4-amino-7-((*tert*-butyldimethylsilyl)oxy)-2,2-dimethylhexahydrobenzo[*d*][1,3]dioxole-5-carboxylate (7)

Pd(OH)$_2$/C at 20% (0.075 g (50 wt%)) was added over a deoxygenated solution of 6 (0.150 g, 0.27 mmol) in AcOEt (6 mL). This mixture was stirred under hydrogen for 15 h at rt. Then, the solution was filtered through Celite and washed with AcOEt. The solvent was dried under vacuum and the residue was purified by flash chromatography (AcOEt/Hex 3 : 1) to give 7 (0.089 g, 0.24 mmol, 92%) as a colorless oil. $[\alpha]_D^{23}$: +66.9 (c 0.5, CHCl$_3$). **^{1}H-NMR (CDCl$_3$, 300 MHz, ppm):** 0.06 (s, 6H, 2× CH$_3$), 0.86 (s, 9H, 3× CH$_3$), 1.33 (s, 3H, CH$_3$), 1.47 (s, 3H, CH$_3$), 1.77 (dtd, J = 13.6, 3.3, 0.8 Hz, 1H, CHH), 1.88 (ddd, J = 13.6, 11.3, 2.7 Hz, 1H, CHH), 2.60 (td, J = 11.2, 3.6 Hz, 1H, CH–CO), 3.01 (dd, J = 11.2, 8.4 Hz, 1H, CH–N), 3.68 (s, 3H, CH$_3$–O), 3.82 (dd, J = 8.4, 5.1 Hz, 1H, CH–O), 3.91–4.00 (m, 1H, CH–O), 4.19 (q, J = 3.0 Hz, CH-OTBS). **^{13}C-NMR (CDCl$_3$, 75 MHz, ppm):** −5.1 (CH$_3$), −5.0 (CH$_3$), 17.9 (C), 25.6 (3× CH$_3$), 26.4 (CH$_3$), 28.3 (CH$_3$), 32.0 (CH$_2$), 42.3 (CH), 51.7 (CH), 54.1 (CH$_3$), 67.2 (CH), 77.8 (CH), 80.4 (CH), 109.1 (C), 175.0 (C=O). **HRMS (ESI$^+$):** calculated for C$_{17}$H$_{34}$NO$_5$Si [M + H]$^+$, 360.2201; found, 360.2200. **IR (ν, cm^{-1}):** 3382 (NH), 1737 (C=O).

(1*S*,2*S*,3*R*,4*S*,5*R*)-2-Amino-3,4,5-trihydroxycyclohexane-1-carboxylic acid (5)

Compound 4 (0.039 g, 0.11 mmol) in 6 M HCl aqueous solution (5 mL) was refluxed for 15 h. The solvent was concentrated in vacuum, and the residue was redissolved in H$_2$O (1 mL). Activated Dowex 50WX4-50 was added, and the mixture was stirred for 1 h. Then, the Dowex was washed with water and MeOH. The compound was released from the resin with a 10% aqueous solution of NH$_3$. The combined aqueous layers were concentrated in vacuum to give 5 (0.018 g, 0.09 mmol, 86%) as a pale-yellow oil. $[\alpha]_D^{23}$: +33.7 (c 1.5, H$_2$O). **^{1}H-NMR (D$_2$O, 300 MHz, ppm):** 2.01 (m, 1H, CHH), 2.24 (m, 1H, CHH), 2.80 (q, J = 4.4 Hz, 1H, CH–CO), 3.49 (dd, J = 10.1, 5.0 Hz, 1H, CH–N), 3.77–3.91 (m, 2H, 2× CH–O), 4.06 (dd, J = 10.1, 2.3 Hz, 1H, CH–O). **^{13}C-NMR (D$_2$O, 75 MHz, ppm):** 29.4 (CH$_2$), 40.0 (CH), 49.5 (CH), 51.8 (CH), 69.7 (CH), 72.3 (CH), 179.7 (C=O). **HRMS (ESI$^+$):** calculated for C$_7$H$_{14}$NO$_5$ [M + H]$^+$, 192.0866; found, 192.0866. **IR (ν, cm^{-1}):** 3340 (NH and OH), 1740 (C=O).

(1*R*,2*S*,3*R*,4*S*,5*R*)-2-Amino-3,4,5-trihydroxycyclohexane-1-carboxylic acid (8)

Compound 7 (0.070 g, 0.19 mmol) in 6 M HCl aqueous solution (8 mL) is refluxed for 15 h. The solvent was concentrated in vacuum, and the residue was redissolved in H$_2$O (1 mL).

8542 | *Org. Biomol. Chem.*, 2023, **21**, 8535–8547

This journal is © The Royal Society of Chemistry 2023

Activated Dowex 50WX4-50 was added, and the mixture was stirred for 1 h. Then, the Dowex was washed with water and MeOH. The compound was released of the resin with a 10% aqueous solution of NH$_3$. The combined aqueous layers were concentrated in vacuum to give **8** (0.031 g, 0.16 mmol, 84%) as pale-yellow oil. $[\alpha]_D^{23}$: −26.9 (c 2.0, H$_2$O). **^{1}H-NMR (D$_2$O, 300 MHz, ppm):** 1.78–2.06 (m, 2H, CH$_2$), 2.68 (td, J = 12.5, 2.8 Hz, 1H, CH–CO), 3.45 (t, J = 10.9 Hz, 1H, CH–N), 3.88–4.03 (m, 2H, 2× CH–O), 4.10 (m, 1H, CH–O). **^{13}C-NMR (D$_2$O, 75 MHz, ppm):** 30.2 (CH$_2$), 41.7 (CH), 53.3 (CH), 68.8 (CH), 69.2 (CH), 71.9 (CH), 179.9 (C=O). **HRMS (ESI$^+$):** calculated for C$_7$H$_{14}$NO$_5$ [M + H]$^+$, 192.0866, found, 192.0866. **IR (ν, cm^{-1}):** 3246 (NH and OH), 1744 (C=O).

Dipeptide 10

Pd(OH)$_2$ at 10% (75 mg, 50 wt%) was added to a deoxygenated solution of dipeptide **9** (Boc-*trans*-(ACHC)$_2$-OBn) (150 mg, 0.327 mmol) in MeOH (7 mL). The mixture was stirred under hydrogen atmosphere for 16 h, then was filtered over Celite and washed with MeOH. The solvent was removed under vacuum to afford dipeptide **10** (135 mg) as a white solid that was used in the next reaction without further purification.

Tripeptide 11

EDCI·HCl (222 mg, 1.159 mmol) was added over a solution of dipeptide **10** (194 mg, 0.527 mmol) in dry DMF (3.8 mL) and the mixture was stirred for 30 min. Compound **7** (189 mg, 0.527 mmol) and DMAP (193 mg, 1.581 mmol) were then added to the former mixture and the stirring followed for 17 h under an argon atmosphere. The solvent was then removed under vacuum, the residue was redissolved in AcOEt (5 mL) and washed with 5 mL portions of HCl (1 M), NaCl (sat.) y NaHCO$_3$ (sat.) and NaCl (sat.). The organic layer was dried over Na$_2$SO$_4$, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (AcOEt/Hex 1 : 1) to afford tripeptide **11** (347 mg, 93%) as a white solid. $[\alpha]_D^{20}$: +33.1 (c 10, CHCl$_3$). **^{1}H-NMR (CDCl$_3$, 300 MHz, ppm):** 0.07 (s, 3H, SiCH$_3$), 0.08 (s, 3H, SiCH$_3$), 0.89 (s, 9H, SiC(CH$_3$)$_3$), 1.06–1.37 (m, 14H, 2× CH$_3$ + 4× CH$_2$), 1.40 (s, 9H, C(CH$_3$)$_3$), 1.62–2.15 (m, 10H, 5× CH$_2$), 2.62–2.79 (m, 2H, 2× CH–CO), 2.99 (m, 1H, CH–CO), 3.59 (m, 4H, OCH$_3$ + NCH), 3.87 (q, J = 9.5 Hz, 1H, NCH), 3.99–4.10 (m, 2H, NCH + OCH), 4.13–4.28 (m, 2H, 2× OCH), 5.83 (d, J = 9.3 Hz, 1H, HN), 6.13 (d, J = 7.1 Hz, 1H, HN), 7.01 (d, J = 8.2 Hz, 1H, HN). **^{13}C-NMR (CDCl$_3$, 75 MHz, ppm):** −4.81 (SiCH$_3$), −4.78 (SiCH$_3$), 18.22 (C), 22.79 (CH$_2$), 24.72 (CH$_2$), 25.19 (CH$_2$), 25.38 (CH$_2$), 25.60 (3× CH$_3$), 25.96 (CH$_3$), 26.59 (CH$_3$), 28.12 (3× CH$_3$), 29.01 (CH$_2$), 29.79 (CH$_2$), 31.85 (2× CH$_2$), 33.79 (CH$_2$), 41.83 (CH–CO), 48.34 (CH–CO), 49.57 (CH–CO), 51.60 (CH$_3$), 52.08 (CH–N), 52.64 (CH–N), 53.47 (CH–N), 67.12 (CH–O), 76.92 (CH–O), 78.30 (CH–O), 79.02 (C, Boc), 109.24 (C), 156.18 (CO, Boc), 173.26 (2× CO), 174.99 (CO). **HRMS (ESI$^+$):** calculated for C$_{36}$H$_{64}$N$_3$O$_9$Si [M + H]$^+$, 710.4405; found 710.4406. **IR (cm^{-1}):** 3327.38 (NH), 1736.29 and 1679.77 (C=O).

Tripeptide 12

LiOH·H$_2$O (50 mg, 1.180 mmol) was added to a solution of dipeptide **11** (336 mg, 0.472 mmol) in THF/MeOH/H$_2$O (1 : 1 : 1) (8 mL) at 0 °C. The mixture was stirred for 24 h at room temperature. The solvent was removed under reduced pressure, the mixture was diluted with a 10% citric acid solution (5 mL) and extracted with Et$_2$O (3 × 10 mL). The combined organic layers were dried over anhydrous Na$_2$SO$_4$, filtered and concentrated to afford tripeptide **12** (301 mg, 92%) as a white solid that was used in the next reaction without further purification.

Dipeptide 13

Dipeptide **9** (Boc-*trans*-(ACHC)$_2$-OBn) (216 mg, 0.472 mmol) was stirred in a mixture of TFA/H$_2$O (1 : 1) (2.4 mL) for 1 h. Then, the solvent was evaporated under vacuum to afford dipeptide **13** (295 mg) as a white solid, which was used in the next reaction without further purification.

Pentapeptide 14

EDCI·HCl (54 mg, 0.282 mmol) was added to a solution of dipeptide **12** (89 mg, 0.128 mmol) in dry DMF (0.91 mL) and the mixture was stirred over 30 min. Then, tripeptide **13** (46 mg, 0.128 mmol) in dry DMF (0.91 mL) and DMAP (47 mg, 0.384 mmol), were added to the mixture and the reaction was further stirred for 21 h under argon atmosphere. Then, the solvent was removed in vacuum, the residue was redissolved in DCM (5 mL) and washed with 5 mL portions of HCl (1 M), NaCl (sat.), NaHCO$_3$ (sat.) and NaCl (sat.). The organic layer was dried over anhydrous Na$_2$SO$_4$, filtered, and concentrated in vacuum. The residue was purified by flash chromatography (DCM/MeOH 1 : 20) to afford **14** (60 mg, 45%) as a white solid. $[\alpha]_D^{23}$: +48.3 (c 1, CH$_2$Cl$_2$). For NMR data see the ESI.‡ **HRMS (ESI$^+$):** calculated for C$_{56}$H$_{89}$N$_5$O$_{11}$NaSi [M + Na]$^+$, 1058.6218; found 1058.6220. **IR:** 3281.07 (NH), 1721.22 and 1644.93 (C=O).

Pentapeptide 15

TBAF (1 M THF solution, 0.7 mL) was added dropwise to a solution of pentapeptide **14** (50 mg, 0.048 mmol) in dry THF (0.78 mL) and the mixture was stirred for 4 days. The solvent was them removed under reduced pressure, the residue was redissolved in DCM (10 mL) and washed with 1 M HCl (3 × 10 mL) and NaCl (10 mL). The combined organic layers were dried over anhydrous Na$_2$SO$_4$, filtered, and concentrated. The residue was purified by flash chromatography (MeOH/DCM 1 : 15) to afford pentapeptide **15** (34 mg, 76%) as a white solid. $[\alpha]_D^{23}$: +34.2 (c 1, CH$_2$Cl$_2$). For NMR data see the ESI.‡ **HRMS (ESI$^+$):** calculated for C$_{50}$H$_{75}$N$_5$NaO$_{11}$ [M + Na]$^+$, 944.5359; found, 944.5355. **IR:** 3369.60 (NH), 1721.09 and 1649.42 (C=O).

Pentapeptide 16

Pentapeptide **15** (18 mg, 0.02 mmol) was stirred in a mixture of AcOH/THF/H$_2$O (0.176 mL) for 29 h at rt. Then, the solvent was removed under reduced pressure and the residue was puri-

This journal is © The Royal Society of Chemistry 2023

Org. Biomol. Chem., 2023, **21**, 8535–8547 | **8543**

fied by flash chromatography (MeOH/DCM 1 : 10) to give pentapeptide **16** (8.5 mg, 50%) as a white solid. $[\alpha]_D^{23}$: +44.0 (c 1, CH_2Cl_2). For NMR data see the ESI.‡ **HRMS (ESI$^+$):** calculated for $C_{47}H_{71}N_5NaO_{11}$ $[M + Na]^+$, 904.5048; found 904.5045. **IR:** 3269.40 (NH), 1723.10 and 1649.50 (C=O).

Infrared spectroscopy

Fourier-transform infrared (FTIR) spectra were acquired using a MIDAC Prospect FT-IR PerkinElmer Spectrum Two spectrometer. Samples were deposited on an ATR diamond accessory as dry solids.

Circular dichroism spectroscopy

Circular dichroism (CD) spectra were acquired with a JASCO DIP-370 optical polarimeter using a 1 mm path length quartz cell (Hellma Analytics, Germany). Wavelength scans were collected between 260 and 195 nm with a 1 nm bandwidth, 1 nm data interval and 100 nm min^{-1} scanning speed.

Samples were prepared by dissolving dry peptide in HPLC-grade methanol (Fisher Scientific) to give 1 mM solutions. Samples of 700, 500, and 100 µM concentration were prepared by serial dilution of the 1 mM stock.

Three scans of each peptide solution were taken and averaged. Solvent blanks were subtracted from the raw spectra and smoothened over 17 data points prior to normalization to molar ellipticity. The CD signal was converted into molar ellipticity ([Θ], deg cm^2 dmol^{-1}) using the equation:

$$[\Theta] = 100 \times \Psi/(l \times c)$$

where Ψ is the raw ellipticity in degrees, l is the path length in decimeters, and c is the molar concentration.

NMR spectroscopy and structure calculation of peptides 14–16. NMR spectra of peptides were recorded on Bruker Avance III 500 and NEO 750 spectrometers operating at 500 MHz and 750 MHz, respectively. The resonance of tetramethylsilane (TMS) was used as chemical shift reference in the ^{1}H NMR experiments (δ_{TMS} = 0.00 ppm). Samples for NMR experiments were prepared by dissolving peptides in 550 µL of deuterated solvent to a final concentration of 1–10 mM. Amide proton temperature coefficients were studied by recording 1D ^{1}H spectra at a series of temperatures in 10 K increments. Values are reported in –ppb K^{-1}. Two-dimensional (2D) ^{1}H homonuclear spectra (COSY, TOCSY, ROESY and NOESY) were recorded using standard pulse sequences. Each 2D spectrum was collected as a data matrix consisting of 2048 (t_2) × 256 (t_1) complex points and a sweep width of 5000 Hz. TOCSY spectra were recorded using the MLEV pulse sequence with a mixing time of 70 ms unless otherwise stated. ROESY experiments were acquired with mixing times of 120 and 200 ms. Spectra were processed using the programs TopSpin and MestreNova. Peptide resonance assignments were obtained using standard strategies based on two-dimensional NMR experiments. The NOEs were classified into three groups of strong, medium, and weak with upper bounds of 2.5, 3.5 and 5.0 Å, respectively. Structural models were calculated by restrained molecular dynamics with XPLOR-NIH[68,69] using the NOE and scalar coupling data. These models were further optimized using

DFT calculations that employed the hybrid density functional M052X[70] with the 6-31+G(d) basis set. DFT calculations were performed using Gaussian 09.[71]

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

References

1 S. H. Gellman, Foldamers: A Manifesto, *Acc. Chem. Res.*, 1998, **31**, 173–180, DOI: **10.1021/ar960298r**.

2 R. P. Cheng, S. H. Gellman and W. F. DeGrado, β-Peptides: From Structure to Function, *Chem. Rev.*, 2001, **101**, 3219–3232, DOI: **10.1021/cr000045i**.

3 D. J. Hill, M. J. Mio, R. B. Prince, T. S. Hughes and J. S. Moore, A Field Guide to Foldamers, *Chem. Rev.*, 2001, **101**, 3893–4012, DOI: **10.1021/cr990120t**.

4 Y.-D. Wu, W. Han, D.-P. Wang, Y. Gao and Y.-L. Zhao, Theoretical Analysis of Secondary Structures of β-Peptides, *Acc. Chem. Res.*, 2008, **41**, 1418–1427, DOI: **10.1021/ar800070b**.

5 P. G. Vasudev, S. Chatterjee, N. Shamala and P. Balaram, Structural Chemistry of Peptides Containing Backbone Expanded Amino Acid Residues: Conformational Features of β, γ, and Hybrid Peptides, *Chem. Rev.*, 2011, **111**, 657–687, DOI: **10.1021/cr100100x**.

6 T. A. Martinek and F. Fülöp, Peptidic foldamers: ramping up diversity, *Chem. Soc. Rev.*, 2012, **41**, 687–702, DOI: **10.1016/j.jasms.2007.08.005**.

7 D. Seebach, S. Abele, J. V. Schreiber, B. Martinoni, A. K. Nussbaum, H. Schild, H. Schulz, H. Hennecke, R. Woessner and F. Bitsch, Biological and Pharmacokinetic Studies with β-Peptides, *Chimia*, 1998, **52**, 734, DOI: **10.2533/chimia.1998.734**.

8 J. Frackenpohl, P. I. Arvidsson, J. V. Schreiber and D. Seebach, The Outstanding Biological Stability ofβ-

8544 | *Org. Biomol. Chem.*, 2023, **21**, 8535–8547

This journal is © The Royal Society of Chemistry 2023

andγ-Peptides toward Proteolytic Enzymes: An In Vitro Investigation with Fifteen Peptidases, *ChemBioChem*, 2001, **2**, 445–455, DOI: **10.1002/1439-7633(20010601)2:6<445::AID-CBIC445>3.0.CO;2-R**.

9 W. S. Horne, L. M. Johnson, T. J. Ketas, P. J. Klasse, M. Lu, J. P. Moore and S. H. Gellman, Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 14751–14756, DOI: **10.1073/pnas.0902663106**.

10 L. M. Johnson, W. S. Horne and S. H. Gellman, Broad Distribution of Energetically Important Contacts across an Extended Protein Interface, *J. Am. Chem. Soc.*, 2011, **133**, 10038–10041, DOI: **10.1021/ja203358t**.

11 L. M. Johnson, D. E. Mortenson, H. G. Yun, W. S. Horne, T. J. Ketas, M. Lu, J. P. Moore and S. H. Gellman, Enhancement of α-Helix Mimicry by an α/β-Peptide Foldamer via Incorporation of a Dense Ionic Side-Chain Array, *J. Am. Chem. Soc.*, 2012, **134**, 7317–7320, DOI: **10.1021/ja302428d**.

12 L. Diao and B. Meibohm, Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides, *Clin. Pharmacokinet.*, 2013, **52**, 855–868, DOI: **10.1007/s40262-013-0079-0**.

13 J. A. Kritzer, O. M. Stephens, D. A. Guarracino, S. K. Reznik and A. Schepartz, β-Peptides as inhibitors of protein–protein interactions, *Bioorg. Med. Chem.*, 2005, **13**, 11–16, DOI: **10.1016/j.bmc.2004.09.009**.

14 V. K. Outlaw, R. W. Cheloha, E. M. Jurgens, F. T. Bovier, Y. Zhu, D. F. Kreitler, O. Harder, S. Niewiesk, M. Porotto, S. H. Gellman and A. Moscona, Engineering Protease-Resistant Peptides to Inhibit Human Parainfluenza Viral Respiratory Infection, *J. Am. Chem. Soc.*, 2021, **143**, 5958–5966, DOI: **10.1021/jacs.1c01565**.

15 D. H. Appella, L. A. Christianson, I. L. Karle, D. R. Powell and S. H. Gellman, β-Peptide Foldamers: Robust Helix Formation in a New Family of β-Amino Acid Oligomers, *J. Am. Chem. Soc.*, 1996, **118**, 13071–13072, DOI: **10.1021/ja963290l**.

16 D. H. Appella, L. A. Christianson, D. A. Klein, D. R. Powell, X. Huang, J. J. Barchi and S. H. Gellman, Residue-based control of helix shape in beta-peptide oligomers., *Nature*, 1997, **387**, 381–384, DOI: **10.1038/387381a0**.

17 L. Kiss and F. Fülöp, Synthesis of Carbocyclic and Heterocyclic β-Aminocarboxylic Acids, *Chem. Rev.*, 2014, **114**, 1116–1169, DOI: **10.1021/cr300454h**.

18 E. A. Porter, X. Wang, H. S. Lee, B. Weisblum and S. H. Gellman, Non-haemolytic beta-amino-acid oligomers, *Nature*, 2000, **404**, 565, DOI: **10.1038/35007145**.

19 T. L. Raguse, E. A. Porter, B. Weisblum and S. H. Gellman, Structure−Activity Studies of 14-Helical Antimicrobial β-Peptides: Probing the Relationship between Conformational Stability and Antimicrobial Potency, *J. Am. Chem. Soc.*, 2002, **124**, 12774–12785, DOI: **10.1021/ja0270423**.

20 E. P. English, R. S. Chumanov, S. H. Gellman and T. Compton, Rational development of beta-peptide inhibi-

tors of human cytomegalovirus entry., *J. Biol. Chem.*, 2006, **281**, 2661–2667, DOI: **10.1074/jbc.M508485200**.

21 T. A. Martinek, A. Hetényi, L. Fülöp, I. M. Mándity, G. K. Tóth, I. Dékány and F. Fülöp, Secondary Structure Dependent Self-Assembly of β-Peptides into Nanosized Fibrils and Membranes, *Angew. Chem., Int. Ed.*, 2006, **45**, 2396–2400, DOI: **10.1002/anie.200504158**.

22 S. Kwon, A. Jeon, S. H. Yoo, I. S. Chung and H.-S. Lee, Unprecedented Molecular Architectures by the Controlled Self-Assembly of a β-Peptide Foldamer, *Angew. Chem., Int. Ed.*, 2010, **49**, 8232–8236, DOI: **10.1002/anie.201003302**.

23 J. Kim, S. Kwon, S. H. Kim, C.-K. Lee, J.-H. Lee, S. J. Cho, H.-S. Lee and H. Ihee, Microtubes with Rectangular Cross-Section by Self-Assembly of a Short β-Peptide Foldamer, *J. Am. Chem. Soc.*, 2012, **134**, 20573–20576, DOI: **10.1021/ja3088482**.

24 K. Kulkarni, N. Habila, M. P. Del Borgo and M.-I. Aguilar, Novel Materials From the Supramolecular Self-Assembly of Short Helical β3-Peptide Foldamers, *Front. Chem.*, 2019, **7**, 70, DOI: **10.3389/fchem.2019.00070**.

25 Z. C. Girvin and S. H. Gellman, Foldamer Catalysis, *J. Am. Chem. Soc.*, 2020, **142**, 17211–17223, DOI: **10.1021/jacs.0c07347**.

26 P. Milbeo, J. Martinez, M. Amblard, M. Calmès and B. Legrand, 1-Aminobicyclo[2.2.2]octane-2-carboxylic Acid and Derivatives As Chiral Constrained Bridged Scaffolds for Foldamers and Chiral Catalysts, *Acc. Chem. Res.*, 2021, **54**, 685–696, DOI: **10.1021/acs.accounts.0c00680**.

27 D. H. Appella, L. A. Christianson, I. L. Karle, D. R. Powell and S. H. Gellman, Synthesis and Characterization of trans-2-Aminocyclohexanecarboxylic Acid Oligomers: An Unnatural Helical Secondary Structure and Implications for β-Peptide Tertiary Structure, *J. Am. Chem. Soc.*, 1999, **121**, 6206–6212, DOI: **10.1021/ja990748l**.

28 J. Applequist, K. A. Bode, D. H. Appella, L. A. Christianson and S. H. Gellman, Theoretical and Experimental Circular Dichroic Spectra of the Novel Helical Foldamer Poly[(1 R, 2 R)- trans -2-aminocyclopentanecarboxylic acid], *J. Am. Chem. Soc.*, 1998, **120**, 4891–4892, DOI: **10.1021/ja9742186**.

29 D. H. Appella, L. A. Christianson, D. A. Klein, M. R. Richards, D. R. Powell and S. H. Gellman, Synthesis and Structural Characterization of Helix-Forming β-Peptides: trans-2-Aminocyclopentanecarboxylic Acid Oligomers, *J. Am. Chem. Soc.*, 1999, **121**, 7574–7581, DOI: **10.1021/ja991185g**.

30 T. A. Martinek, I. M. Mándity, L. Fülöp, G. K. Tóth, E. Vass, M. Hollósi, E. Forró and F. Fülöp, Effects of the Alternating Backbone Configuration on the Secondary Structure and Self-Assembly of β-Peptides, *J. Am. Chem. Soc.*, 2006, **128**, 13539–13544, DOI: **10.1021/ja063890c**.

31 I. M. Mándity, E. Wéber, T. A. Martinek, G. Olajos, G. K. Tóth, E. Vass and F. Fülöp, Design of Peptidic Foldamer Helices: A Stereochemical Patterning Approach, *Angew. Chem., Int. Ed.*, 2009, **48**, 2171–2175, DOI: **10.1111/j.1399-3011.1994.tb01023.x**.

This journal is © The Royal Society of Chemistry 2023

Org. Biomol. Chem., 2023, **21**, 8535–8547 | **8545**

32 A. Hetényi, Z. Szakonyi, I. M. Mándity, É. Szolnoki, G. K. Tóth, T. A. Martinek and F. Fülöp, Sculpting the β-peptide foldamer H12 helix via a designed side-chain shape, *Chem. Commun.*, 2009, 177–179, DOI: **10.1039/B812114A**.

33 I. M. Mándity, L. Fülöp, E. Vass, G. K. Tóth, T. A. Martinek and F. Fülöp, Building β-Peptide H10/12 Foldamer Helices with Six-Membered Cyclic Side-Chains: Fine-Tuning of Folding and Self-Assembly, *Org. Lett.*, 2010, **12**, 5584–5587, DOI: **10.1021/ol102494m**.

34 X. Wang, J. F. Espinosa and S. H. Gellman, 12-Helix Formation in Aqueous Solution with Short β-Peptides Containing Pyrrolidine-Based Residues, *J. Am. Chem. Soc.*, 2000, **122**, 4821–4822, DOI: **10.1021/ja000093k**.

35 É. Szolnoki, A. Hetényi, T. A. Martinek, Z. Szakonyi and F. Fülöp, Self-association-driven transition of the β-peptidic H12 helix to the H18 helix, *Org. Biomol. Chem.*, 2012, **10**, 255–259, DOI: **10.1039/C1OB06627G**.

36 L. Kiss, I. M. Mándity and F. Fülöp, Highly functionalized cyclic β-amino acid moieties as promising scaffolds in peptide research and drug design, *Amino Acids*, 2017, **49**, 1441–1455, DOI: **10.1007/s00726-017-2439-9**.

37 F. Sussman, V. M. Sánchez-Pedregal, J. C. Estévez, R. Balo, J. Jiménez-Barbero, A. Ardá, A. Gimeno, M. Royo, M. C. Villaverde and R. J. Estévez, Environmental Effects Determine the Structure of Potential β-Amino Acid Based Foldamers, *Chem. – Eur. J.*, 2018, **24**, 10625–10629, DOI: **10.1002/chem.201801953**.

38 M. Lee, J. Shim, P. Kang, M.-G. Choi and S. H. Choi, Stabilization of 11/9-helical α/β-peptide foldamers in protic solvents, *Chem. Commun.*, 2016, **52**, 5950–5952, DOI: **10.1039/C6CC01189F**.

39 S. H. Choi, M. Ivancic, I. A. Guzei and S. H. Gellman, Structural Characterization of Peptide Oligomers Containing (1 R, 2 S)-2-Aminocyclohexanecarboxylic Acid (*cis*-ACHC): Structural Characterization of Peptide Oligomers, *Eur. J. Org. Chem.*, 2013, 3464–3469, DOI: **10.1002/ejoc.201300118**.

40 T. L. Raguse, J. R. Lai, P. R. LePlae and S. H. Gellman, Toward β-Peptide Tertiary Structure: Self-Association of an Amphiphilic 14-Helix in Aqueous Solution, *Org. Lett.*, 2001, **3**, 3963–3966, DOI: **10.1021/ol016868r**.

41 P. R. LePlae, J. D. Fisk, E. A. Porter, B. Weisblum and S. H. Gellman, Tolerance of Acyclic Residues in the β-Peptide 12-Helix: Access to Diverse Side-Chain Arrays for Biological Applications, *J. Am. Chem. Soc.*, 2002, **124**, 6820–6821, DOI: **10.1021/ja017869h**.

42 T. L. Raguse, J. R. Lai and S. H. Gellman, Environment-Independent 14-Helix Formation in Short β-Peptides: Striking a Balance between Shape Control and Functional Diversity, *J. Am. Chem. Soc.*, 2003, **125**, 5592–5593, DOI: **10.1021/ja0341485**.

43 W. C. Pomerantz, T. L. R. Grygiel, J. R. Lai and S. H. Gellman, Distinctive Circular Dichroism Signature for 14-Helix-Bundle Formation by β-Peptides, *Org. Lett.*, 2008, **10**, 1799–1802, DOI: **10.1021/ol800622e**.

44 C. Wang, N. A. Biok, K. Nayani, X. Wang, H. Yeon, C.-K. Derek Ma, S. H. Gellman and N. L. Abbott, Cationic Side Chain Identity Directs the Hydrophobically Driven Self-Assembly of Amphiphilic β-Peptides in Aqueous Solution, *Langmuir*, 2021, **37**, 3288–3298, DOI: **10.1021/acs.langmuir.0c03255**.

45 D. H. Appella, J. J. Barchi, S. R. Durell and S. H. Gellman, Formation of Short, Stable Helices in Aqueous Solution by β-Amino Acid Hexamers, *J. Am. Chem. Soc.*, 1999, **121**, 2309–2310, DOI: **10.1021/ja983918n**.

46 J. A. Kritzer, J. Tirado-Rives, S. A. Hart, J. D. Lear, W. L. Jorgensen and A. Schepartz, Relationship between Side Chain Structure and 14-Helix Stability of β 3 -Peptides in Water, *J. Am. Chem. Soc.*, 2005, **127**, 167–178, DOI: **10.1021/ja0459375**.

47 A. Hetényi, G. K. Tóth, C. Somlai, E. Vass, T. A. Martinek and F. Fülöp, Stabilisation of Peptide Foldamers in an Aqueous Medium by Incorporation of Azapeptide Building Blocks, *Chem. – Eur. J.*, 2009, **15**, 10736–10741, DOI: **10.1002/chem.200900724**.

48 L. Kiss, E. Forró, T. A. Martinek, G. Bernáth, N. De Kimpe and F. Fülöp, Stereoselective synthesis of hydroxylated β-aminocyclohexanecarboxylic acids, *Tetrahedron*, 2008, **64**, 5036–5043, DOI: **10.1016/j.tet.2008.03.068**.

49 E. Forró, L. Schönstein, L. Kiss, A. Vega-Peñaloza, E. Juaristi and F. Fülöp, Direct Enzymatic Route for the Preparation of Novel Enantiomerically Enriched Hydroxylated β-Amino Ester Stereoisomers, *Molecules*, 2010, **15**, 3998–4010, DOI: **10.3390/molecules15063998**.

50 M. Risseeuw, M. Overhand, G. W. J. Fleet and M. I. Simone, A compendium of cyclic sugar amino acids and their carbocyclic and heterocyclic nitrogen analogues, *Amino Acids*, 2013, **45**, 613–689, DOI: **10.1007/s00726-013-1521-1**.

51 M. Lee, T. L. Raguse, M. Schinnerl, W. C. Pomerantz, X. Wang, P. Wipf and S. H. Gellman, Origins of the High 14-Helix Propensity of Cyclohexyl-Rigidified Residues in β-Peptides, *Org. Lett.*, 2007, **9**, 1801–1804, DOI: **10.1021/ol070511r**.

52 F. Fernández, A. G. Fernández, R. Balo, V. M. Sánchez-Pedregal, M. Royo, R. G. Soengas, R. J. Estévez and J. C. Estévez, Polyhydroxylated Cyclopentane β-Amino Acids Derived from d -Mannose and d -Galactose: Synthesis and Protocol for Incorporation into Peptides, *ACS Omega*, 2022, **7**, 2002–2014, DOI: **10.1021/acsomega.1c05468**.

53 M. A. González, A. M. Estévez, M. Campos, J. C. Estévez and R. J. Estévez, Protocol for the Incorporation of γ-Amino Acids into Peptides: Application to (−)-Shikimic Acid Based 2-Amino-Methylcyclohexanecarboxylic Acids, *J. Org. Chem.*, 2018, **83**, 1543–1550, DOI: **10.1021/acs.joc.7b02671**.

54 An initial version of this work was deposited in ChemRxiv on December 29, 2022, reference: D. Reza, R. Balo, J. M. Otero, A. M. Fletcher, R. García-Fandino, V. M. Sanchez-Pedregal, S. G. Davies, R. J. Estevez and J. C. Estevez, β-Peptides incorporating polyhydroxylated cyclohexane β-amino acids: synthesis and conformational study, *ChemRxiv*, DOI: **10.26434/chemrxiv-2022-zdb5j**.

55 J. C. Borah, Shikimic acid: a highly prospective molecule in pharmaceutical industry, *Curr. Sci.*, 2015, **109**, 8, DOI: **10.18520/v109/i9/1672-1679**.

56 M. A. González-Castro, D. L. Poole, J. C. Estévez, G. W. J. Fleet and R. J. Estévez, A stereoselective transformation of (−)-shikimic acid into (3R,4S,5R,7R)-7-(hydroxymethyl)azepane-3,4,5-triol, a potential glycosidase inhibitor, *Tetrahedron: Asymmetry*, 2015, **26**, 320–323, DOI: **10.1016/j.tetasy.2015.02.005**.

57 S. G. Davies and O. Ichihara, Asymmetric synthesis of R-β-amino butanoic acid and S-β-tyrosine: Homochiral lithium amide equivalents for Michael additions to α,β-unsaturated esters., *Tetrahedron: Asymmetry*, 1991, **2**, 183–186, DOI: **10.1016/S0957-4166(00)82354-X**.

58 J. F. Costello, S. G. Davies and O. Ichihara, Origins of the high stereoselectivity in the conjugate addition of lithium (α-methylbenzyl)benzylamide to t-butyl cinnamate, *Tetrahedron: Asymmetry*, 1994, **5**, 1999–2008, DOI: **10.1016/S0957-4166(00)86275-8**.

59 S. G. Davies, O. Ichihara, I. Lenoir and I. A. S. Walters, Asymmetric synthesis of (−)-(1R,2S)-cispentacin and related cis- and trans-2-amino cyclopentane- and cyclohexane-1-carboxylic acids, *J. Chem. Soc., Perkin Trans. 1*, 1994, 1411–1415, DOI: **10.1039/P19940001411**.

60 G. Montalvo, M. M. Waegele, S. Shandler, F. Gai and W. F. DeGrado, Infrared Signature and Folding Dynamics of a Helical β-Peptide, *J. Am. Chem. Soc.*, 2010, **132**, 5616–5618, DOI: **10.1021/ja100459a**.

61 L. Zhai, M. Nara, Y. Otani and T. Ohwada, Unexpectedly rigid short peptide foldamers in which NH–π and CH–π interactions are preserved in solution, *Chem. Commun.*, 2021, **57**, 8344–8347, DOI: **10.1039/D1CC02998C**.

62 R. W. Woody, *Circular Dichroism: Principles and Applications*, VCH Publishers, New York, 1994.

63 S. Yu. Venyaminov and J. T. Yang, in *Circular Dichroism and the Conformational Analysis of Biomolecules*, ed. G. D. Fasman, Springer US, Boston, MA, 1996, pp. 69–107.

64 A. Glättli, X. Daura, D. Seebach and W. F. van Gunsteren, Can One Derive the Conformational Preference of a β-Peptide from Its CD Spectrum?, *J. Am. Chem. Soc.*, 2002, **124**, 12972–12978, DOI: **10.1021/ja020758d**.

65 J. J. Barchi, X. Huang, D. H. Appella, L. A. Christianson, S. R. Durell and S. H. Gellman, Solution Conformations of Helix-Forming β-Amino Acid Homooligomers, *J. Am. Chem. Soc.*, 2000, **122**, 2711–2718, DOI: **10.1021/ja9930014**.

66 A. Pardi, M. Billeter and K. Wüthrich, Calibration of the angular dependence of the amide proton-Cα proton coupling constants, 3JHNα, in a globular protein, *J. Mol. Biol.*, 1984, **180**, 741–751, DOI: **10.1016/0022-2836(84)90035-4**.

67 B. Vögeli, J. Ying, A. Grishaev and A. Bax, Limits on variations in protein backbone dynamics from precise measurements of scalar couplings., *J. Am. Chem. Soc.*, 2007, **129**, 9377–9385, DOI: **10.1021/ja070324o**.

68 C. D. Schwieters, J. J. Kuszewski, N. Tjandra and G. M. Clore, The Xplor-NIH NMR molecular structure determination package, *J. Magn. Reson.*, 2003, **160**, 65–73, DOI: **10.1016/S1090-7807(02)00014-9**.

69 C. Schwieters, J. Kuszewski and G. M. Clore, Using Xplor–NIH for NMR molecular structure determination, *Prog. Nucl. Magn. Reson. Spectrosc.*, 2006, **48**, 47–62, DOI: **10.1016/j.pnmrs.2005.10.001**.

70 Y. Zhao and D. G. Truhlar, Density Functionals for Noncovalent Interaction Energies of Biological Importance, *J. Chem. Theory Comput.*, 2007, **3**, 289–300, DOI: **10.1021/ct6002719**.

71 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox. *GAUSSIAN 09 (Revision E.01)*, Gaussian Inc., Wallingford CT, 2013.

72 E. Arunan, G. R. Desiraju, R. A. Klein, J. Sadlej, S. Scheiner, I. Alkorta, D. C. Clary, R. H. Crabtree, J. J. Dannenberg, P. Hobza, H. G. Kjaergaard, A. C. Legon, B. Mennucci and D. J. Nesbitt, Definition of the hydrogen bond (IUPAC Recommendations 2011), *Pure Appl. Chem.*, 2011, **83**, 1637–1641, DOI: **10.1351/PAC-REC-10-01-02**.

This journal is © The Royal Society of Chemistry 2023

Org. Biomol. Chem., 2023, **21**, 8535–8547 | **8547**